
Current Price | $4.98 | Mkt Cap | $223.3M |
---|---|---|---|
Open | $5.22 | P/E Ratio | -96.89 |
Prev. Close | $4.98 | Div. (Yield) | $0.00 (0.0%) |
Daily Range | $4.82 - $5.22 | Volume | 109,505 |
52-Wk Range | $3.72 - $5.72 | Avg. Daily Vol. | 33,231 |
Current Price | $4.98 | Mkt Cap | $223.3M |
---|---|---|---|
Open | $5.22 | P/E Ratio | -96.89 |
Prev. Close | $4.98 | Div. (Yield) | $0.00 (0.0%) |
Daily Range | $4.82 - $5.22 | Volume | 109,505 |
52-Wk Range | $3.72 - $5.72 | Avg. Daily Vol. | 33,231 |
The best Bull and Bear pitches based on recency and number of recommendations.
Kamada is kind of a weird company. Aside from being an Israeli biotech, which I've found to be a highly weird niche of the biopharma sector, the company offers a strange mix of marketed products and therapeutics in clinical development.The company's… More
There are no pitches that meet the Top Bear criteria. Explain
If this upsets you, start recommending pitches below!
Read the most recent pitches from players about KMDA.
Recs
Kamada is kind of a weird company. Aside from being an Israeli biotech, which I've found to be a highly weird niche of the biopharma sector, the company offers a strange mix of marketed products and therapeutics in clinical development.The company's lead product, Glassia, is a plasma-purified alpha-1 antitrypsin (AAT) administered intravenously for congenital AAT deficiency. It may seem odd that Kamada's market capitalization is only 250M given the high valuation assigned to other companies marketing enzyme replacement therapies and other protein therapeutics for rare diseases, but Glassia is in fact the fourth plasma derived AAT to become available, and intravenous AAT doesn't seem to be the cornerstone of therapy for AAT deficiency.
Kamada IPO'd in early 2013 and seems to have dedicated the bulk of the cash they raised to their developmental pipeline, which mainly consists of a novel inhalational AAT as well as broadening the indications for Glassia. That effort took a serious body blow with the failure of a European phase II/III trial of inhaled AAT to meet the primary endpoint in May, resulting in a substantial haircut in share price from a high of 18 to a recent low of 7. Nevertheless, Kamada seems to be pressing ahead with new trials of inhaled AAT in emphysema from AAT deficiency. Trials of Glassia in GVHD and type I diabetes are also in progress.
Kamada's long-term prospects seem dubious but at some point the share price will level off and begin to rise again as traders become optimistic about trials in progress. I'm not sure that time has come, but I'll flag Kamada with a green thumb here to remind me to keep a close eye on the price movement as the pipeline progresses.
Find the members with the highest scoring picks in KMDA.
XMFCouchSurfer (48.62) Score: +143.73
The Score Leader is the player with the highest score across all their picks in KMDA.
Top Pick |
Member Name |
Member Rating |
Start Date |
Call |
Time Frame |
Start Price |
Stock Gain |
Index Gain |
Score | Commentary |
---|---|---|---|---|---|---|---|---|---|---|
XMFCouchSurfer | 48.62 | 7/29/2014 |
![]() |
5Y | $7.19 | -30.74% | +113.00% | +143.73 | 0 Comment | |
LifeScientist | 23.45 | 6/25/2020 |
![]() |
3W | $8.97 | -44.48% | +36.70% | +81.18 | 0 Comment | |
sln | 44.93 | 7/6/2021 |
![]() |
5Y | $5.85 | -14.87% | -3.14% | +11.74 | 0 Comment | |
Under5 | 56.18 | 12/21/2022 |
![]() |
5Y | $4.15 | +20.00% | +9.64% | +10.36 | 0 Comment | |
eagles777 | 64.71 | 5/25/2023 |
![]() |
3Y | $5.40 | -7.78% | +1.31% | -9.09 | 0 Comment | |
alpagan | < 20 | 1/5/2021 |
![]() |
5Y | $6.50 | -23.38% | +14.15% | -37.53 | 0 Comment | |
LeetradeMichael | < 20 | 6/22/2020 |
![]() |
5Y | $8.32 | -40.14% | +35.35% | -75.49 | 0 Comment | |
BravoBevo | 99.97 | 8/19/2020 |
![]() |
5Y | $10.35 | -51.88% | +23.81% | -75.69 | 0 Comment | |
cvdynasty0 | 99.82 | 9/4/2014 |
![]() |
5Y | $5.82 | -14.43% | +108.84% | -123.27 | 0 Comment | |
zzlangerhans | 99.41 | 7/3/2014 |
![]() |
1Y | $7.21 | -30.93% | +112.15% | -143.08 | 1 Comment |
See what the Wall Street professionals think, according to their public statements and filings.